Memphasys Limited (MEM.AX)

0.0090 0.0000 (0.00%) At close: 04:10PM AEST

Memphasys Limited

30 Richmond Road
Homebush, NSW 2140
Australia
61 2 8415 7300
https://www.memphasys.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Dr. David Ali	Acting CEO & Executive Director	213.37k	N/A	N/A
Pablo Neyertz	Director of Finance	174.49k	N/A	N/A
Associate Prof. Hassan Bakos	Director of Operations	237.59k	N/A	N/A
Prof. R. John Aitken Ph.D., ScD FRSE	Scientific Director	249.27k	N/A	N/A
Mr. Andrew Metcalfe B.Bus, CPA, FGIA, MAICD	Company Secretary	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. It primarily develops Felix, a device separates sperm from raw semen by electrophoresis process for use in human IVF procedures. In addition, the company's product pipeline include ROSA, a rapid oxidative stress assay; Samson Device, rapid equine pregnancy prediction assay; SemPort, a system that allows transport of semen; and AI-Port. Further, it provides ambient temperature storage product for human sperm. Memphasys Limited was incorporated in 2006 and is based in Homebush, Australia.

Corporate governance

Memphasys Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.